Published in Clin Exp Gastroenterol on January 19, 2017
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Diagnosis and management of autoimmune hepatitis. Hepatology (2010) 5.27
Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology (2010) 5.00
FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol (2012) 3.57
Lupoid hepatitis. Lancet (1956) 2.82
Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. J Hepatol (2014) 2.68
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis. Hepatology (2014) 2.29
Autoimmune hepatitis in childhood: a 20-year experience. Hepatology (1997) 1.97
Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology (2005) 1.89
Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology (1998) 1.85
Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol (2004) 1.84
Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol (2011) 1.56
Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol (2010) 1.52
Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics (1996) 1.50
Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci (2003) 1.37
Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med (1999) 1.28
A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology (1997) 1.25
Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology (2006) 1.24
EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol (2015) 1.23
Autoimmune hepatitis. Lancet (2013) 1.09
Autoimmune hepatitis triggered by statins. J Clin Gastroenterol (2006) 1.06
Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol (1999) 1.06
Aetiopathogenesis of autoimmune hepatitis. J Autoimmun (2009) 1.04
Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology (2002) 1.02
Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology (1999) 1.01
Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther (1994) 1.00
Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance. Hepatology (2012) 0.99
Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol (2006) 0.95
Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology (2012) 0.95
Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol (2002) 0.94
High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol (2000) 0.93
Autoimmune hepatitis and overlap syndromes. Clin Liver Dis (2002) 0.93
Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology (2000) 0.93
Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol (2010) 0.92
Hepatitis resulting from liver-specific expression and recognition of self-antigen. J Autoimmun (2008) 0.92
Differences in immune recognition of cytochrome P4502D6 by liver kidney microsomal (LKM) antibody in autoimmune hepatitis and chronic hepatitis C virus infection. Clin Exp Immunol (1994) 0.91
Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol (1994) 0.90
Effects and regulation of autoreactive CD8+ T cells in a transgenic mouse model of autoimmune hepatitis. Gastroenterology (2010) 0.90
Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. Clin Gastroenterol Hepatol (2013) 0.89
Human leukocyte antigen class II haplotypes affect clinical characteristics and progression of type 1 autoimmune hepatitis in Japan. PLoS One (2014) 0.89
Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis? Hum Pathol (2007) 0.89
Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int (2008) 0.88
A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol (2008) 0.87
Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study. Dig Liver Dis (2014) 0.86
Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity (2002) 0.86
Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology (1990) 0.86
Natural History of Patients Presenting with Autoimmune Hepatitis and Coincident Nonalcoholic Fatty Liver Disease. Dig Dis Sci (2016) 0.85
Clinical features of 89 patients with autoimmune hepatitis in Nagasaki Prefecture, Japan. J Gastroenterol (1999) 0.85
Fatal chronic active Epstein-Barr virus infection mimicking autoimmune hepatitis. Eur J Gastroenterol Hepatol (2004) 0.84
Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis. Hepatol Res (2007) 0.83
HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J Hepatol (2006) 0.83
HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1. Genes Immun (2015) 0.83
Using GWAS to identify genetic predisposition in hepatic autoimmunity. J Autoimmun (2015) 0.83
Clinical Profile and HLA Typing of Autoimmune Hepatitis From Pakistan. Hepat Mon (2013) 0.81
Autoimmune hepatitis: East meets west. J Gastroenterol Hepatol (2015) 0.81
Specificity of antinuclear antibodies in primary biliary cirrhosis. Ann Rheum Dis (1995) 0.80
Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis. Hepatol Int (2009) 0.80
Role of Histopathology in Autoimmune Hepatitis. Dig Dis (2015) 0.79
Prevalence of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol (2011) 0.79
A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. Aliment Pharmacol Ther (2016) 0.78
Genetic factors affect the etiology, clinical characteristics and outcome of autoimmune hepatitis. Clin J Gastroenterol (2015) 0.78
Immunotoxicology of the liver: adverse reactions to drugs. J Hepatol (1997) 0.78
Human leucocyte antigens and pediatric autoimmune liver disease: diagnosis and prognosis. Eur J Pediatr (2015) 0.78
Clinicopathological study of primary biliary cirrhosis with interface hepatitis compared to autoimmune hepatitis. World J Gastroenterol (2014) 0.77
Possible benefit of splenectomy in liver transplantation for autoimmune hepatitis. Hepatobiliary Pancreat Dis Int (2014) 0.77
Centrilobular zonal necrosis as a hallmark of a distinctive subtype of autoimmune hepatitis. Eur J Gastroenterol Hepatol (2016) 0.77
Living-donor liver transplantation for autoimmune hepatitis and autoimmune hepatitis-primary biliary cirrhosis overlap syndrome. Hepatol Res (2012) 0.77
Splenectomy prolongs the effects of corticosteroids in mouse models of autoimmune hepatitis. Gastroenterology (2013) 0.77
Autoimmune hepatitis in older patients. Age Ageing (1997) 0.77
Immunogenetics in liver disease. Baillieres Clin Gastroenterol (1996) 0.76
Type 1 and type 2 autoimmune hepatitis in adults share the same clinical phenotype. Aliment Pharmacol Ther (2015) 0.76
Rapid corticosteroid tapering: Important risk factor for type 1 autoimmune hepatitis relapse in Japan. Hepatol Res (2014) 0.76
Meta-analysis: the relationship between CTLA-4 +49 A/G polymorphism and primary biliary cirrhosis and type I autoimmune hepatitis. Immunol Invest (2015) 0.76
Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States. Int J Med Sci (2004) 0.76
Possible autoimmune hepatitis induced after chronic active Epstein-Barr virus infection. Clin J Gastroenterol (2013) 0.76
Chronic active Epstein-Barr virus infection mimicking autoimmune hepatitis exacerbation in a patient with systemic lupus erythematosus. Lupus (2014) 0.76
A meta-analysis of ursodeoxycholic acid therapy versus combination therapy with corticosteroids for PBC-AIH-overlap syndrome: evidence from 97 monotherapy and 117 combinations. Prz Gastroenterol (2015) 0.76
Natural history and outcomes in drug-induced autoimmune hepatitis. Hepatol Res (2015) 0.76
Non-alcoholic fatty liver disease (NAFLD) potentiates autoimmune hepatitis in the CYP2D6 mouse model. J Autoimmun (2016) 0.76
Bile ductal injury and ductular reaction are frequent phenomena with different significance in autoimmune hepatitis. Liver Int (2016) 0.76
Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis. United European Gastroenterol J (2015) 0.76
Evaluation of the role of HLA-DR antigens in Japanese type 1 autoimmune hepatitis. BMC Gastroenterol (2015) 0.75
Diagnostic difficulties, therapeutic strategies, and performance of scoring systems in patients with autoimmune hepatitis and concurrent hepatitis B/C. Scand J Gastroenterol (2013) 0.75